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Mass treatment with statins
True informed choice will require wholesale changes to the way we gather and communicate
evidence
Ben Goldacre research fellow in epidemiology, Liam Smeeth professor of clinical epidemiology
London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
In broad terms, statins are cheap and more likely to do good
than harm. But broad terms may no longer be sufficient. The
UK National Institute for Health and Care Excellence (NICE)
now recommends offering a statin to anyone with more than a
10% 10 year risk of a cardiovascular event, estimated to be 25%
of the population aged 30-85 years.1Whenwe offer a preventive
drug to such large numbers of healthy people, we are a long
way from the doctor treating a sick patient. In some respects,
we are less like doctors and more like a life insurance sales
team: offering occasional, possibly life changing, benefits, many
years from now, in exchange for small ongoing inconvenience
and cost. This represents a new kind of medicine, and delivering
informed choice that reflects differing patient preferences will
require wholesale structural improvements in how we gather
and communicate research evidence.
The current data on statins have many avoidable shortcomings.
Important questions on comparative efficacy, and efficacy in
different risk strata, have never been adequately answered.2 3
We still do not know the difference, for example, in mortality
benefits and side effects between high and low dose atorvastatin
treatment in the new primary prevention population at 10% risk.
Perhaps more importantly, we lack reliable information from
randomised trials on common symptomatic side effects of
statins.4-6
This persisting uncertainty about the precise risks and benefits
of statins is a serious barrier to informed patient choice; after
two decades of widespread statin prescription, it also shows that
we have so far failed to implement the core principles of
evidence based medicine. Cardiovascular disease is the most
common cause of death in the United Kingdom, the outcomes
are comparatively straightforward to ascertain, and statins are
the most commonly prescribed class of drug in the NHS. That
should be enough motivation and clinical experience to resolve
any uncertainty.
Gathering evidence of benefit from modestly effective
preventive treatments in low risk participants poses specific
challenges for researchers. It requires large numbers of
participants and long follow-up times, which both drive up costs.
Here, however, the NHS offers a unique opportunity for
innovation.7 When comparing widely used treatments that are
known to be safe and effective, it should be trivial to embed
randomised trials unobtrusively into routine clinical activity,
using cheap, routinely collected electronic health record data
for outcomes. A comparison of high and lower intensity statin
treatment in a low risk population would be one such example.
We recently attempted a similar trial but faced numerous
expensive regulatory barriers that were disproportionate to the
risks.8
There are also important challenges around communicating
evidence effectively. Here, even NICE falls short. Although
doctors are told they must give clear information to patients on
the benefits of treatment, at high and low intensity, at each level
of risk, this information cannot be found in the 302 page
guideline. Yet such data are vital, because different people give
differing weights to different aspects of risk and benefit: some
want longevity at any cost, for example, while others regard
even mild side effects as an affront.
The best solution is likely to involve decision making
tools9 10—numerical printouts that are tailored to patients’ own
risks—if these can be integrated seamlessly into electronic health
record systems, validated, and made into attractive and helpful
products.11 Sadly, such tools do not receive funding or attention
on the same scale as even generic drugs. Consequently, their
use is patchy and often requires laborious manual data entry. If
NICE recommended the information as clearly as it recommends
the pill, this might help create a demand, a market, and funding
within the NHS.
Currently, however, NICE seems ambiguous about its core
recommendations. The press release and promotional activity
around the guideline emphasised lifestyle changes and the need
for patients to receive clear information on the benefits of
treatment.12 However, the guideline itself has a different
emphasis: of eight “key priority recommendations” for
implementation, four focus on which tool best identifies patients
for treatment, and four focus on atorvastatin. None mentions
lifestyle or communicating evidence on treatment options. NICE
summarises large numbers of randomised trials on interventions
that target individuals to improve diet and encourage exercise,
most with negative results, yet it still recommends these
interventions. Lifestyle change is likely to deliver large health
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benefits well beyond lipid lowering, but there is no good
evidence that people eat better diets, or domore exercise, simply
because they are told to. They are more likely change their
behaviour when changes in their economic, social, and cultural
context make it easy for them to do so. This requires major
shifts in—for example—national policy, driven by public health.
Such shifts are harder to deliver and fund than drugs or advice.
There are similar challenges in delivering the information
revolution necessary for informed choice on mass prescription.
Doctors are unlikely to start giving patients clear numerical
information simply because they are told to do so. They might
do so if NICE can recommend information tools with the same
force as when it recommends drugs, and if it becomes as easy
to give contextual numerical advice as it is to print a
prescription. Similarly, history shows that trials on important
difficult questions will not appear simply because we need
knowledge. They will flow more freely if we can remove
disproportionate regulatory barriers, reduce the cost of
information, and make trial participation convenient and
uncomplicated.
Mass prescription for modest individual benefit is new. Truly
informed choice will require more than good intentions. We
will need better data, from bigger trials, and better risk
communication than for conventional medical treatment.
Delivering this will require us to embed the gathering,
communication, and implementation of evidence as seamlessly
and cheaply as possible into the everyday routine of medicine.
Without such innovation in the use of medical data, we can say
only that statins are—broadly speaking—likely to domore good
than harm. That is not good enough.
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